Nanoform

Pharmaceutical Contract Manufacturingnanoform.fi

Nanoform Finland Plc is a Helsinki-based pharmaceutical nanotechnology company that uses its proprietary Nanoforming platform to develop nanoformed medicines and provide cGMP contract manufacturing, serving pharmaceutical companies through licensing, R&D collaborations, and API supply.

Company typePrivate
Founded2015
HeadquartersHelsinki, Finland
Headcount101–250
GTM typeB2B
OfferingHardware or Manufacturing

What Nanoform does

Nanoform Finland Plc is a Helsinki-based, publicly listed (Nasdaq Helsinki: NANOFH) pharmaceutical nanotechnology company that uses a proprietary Nanoforming Technology platform to reduce active pharmaceutical ingredients (APIs) to the nanoscale, improving drug solubility and bioavailability. The company was founded in 2015 and operates with a headcount of 101-250 employees. Its product portfolio comprises three branded nanoformed drug candidates — Nanoenzalutamide (with a planned first European market launch in 2028), Nanoapalutamide (in clinical development, supported by a EUR 5M Business Finland R&D loan), and Nanotrastuzumab (which the company reports matches the performance of Herceptin Hylecta) — alongside cGMP contract manufacturing services for nanoformed APIs used in clinical trials and commercial supply. The Nanoforming Technology addresses one of the most cited challenges in pharmaceutical development: poor aqueous solubility of active compounds, which limits bioavailability of roughly 40% of new chemical entities.

Nanoform firmographics

Firmographics

Name: Nanoform
Legal name: Nanoform Finland Plc
Website: https://nanoform.fi
Company type: Private
Founded year: 2015
Operating status: Operating
Headcount range: 101–250 employees
Short description: Nanoform Finland Plc is a Helsinki-based pharmaceutical nanotechnology company that uses its proprietary Nanoforming platform to develop nanoformed medicines and provide cGMP contract manufacturing, serving pharmaceutical companies through licensing, R&D collaborations, and API supply.
Ownership category
akta.pro rank

Nanoform industry classification

Industry

Product category: Pharmaceutical Contract Manufacturing
NAICS: Pharmaceutical Preparation Manufacturing (325412), Research and Development in Nanotechnology (541713), Pharmaceutical and Medicine Manufacturing (32541)
SIC: Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry: CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
akta.pro secondary industries: Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

Nanoparticle drug formulation
Pharmaceutical contract manufacturing
CGMP API manufacturing
Nanoformed medicines
Drug delivery platforms

Where Nanoform is headquartered

Location

Headquarters

HQ city: Helsinki
HQ country: Finland
HQ region: Europe

Offices1 record

Markets served

Nanoform business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Supply Chain, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

NanoImproved Medicines Commercialization: Revenue from commercialization of proprietary nanoformed medicines including Nanoenzalutamide and Nanoapalutamide. First European market launch planned for 2028.
Contract Manufacturing Services: Manufacturing and licensing of nanoformed APIs for clinical trials and commercial supply under cGMP certifications.
R&D Collaboration and Licensing: Research and development partnerships with pharmaceutical companies for nanoparticle-enabled formulation platforms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Nanoform product offering

Product offering

Core offering

Nanoform develops and manufactures nanoformed pharmaceutical products using its proprietary nanoparticle-enabled formulation technology, which improves the bioavailability and performance of active pharmaceutical ingredients (APIs). The company produces proprietary branded nanoformed medicines such as Nanoapalutamide, Nanoenzalutamide, and Nanotrastuzumab, and provides cGMP-compliant contract manufacturing services for nanoformed APIs for clinical trials and commercial supply.

Product overview

Nanoform operates as a nanomedicine company developing nanoformed pharmaceutical products and providing nanoparticle-enabled formulation services. The product portfolio includes branded nanoformed medicines such as Nanoapalutamide, Nanoenzalutamide, and Nanotrastuzumab, alongside GMP contract manufacturing services for nanoformed APIs. The company holds European commercial cGMP manufacturing licenses from FIMEA and is expanding manufacturing capabilities in the US market.

Differentiator

Problem solved

Functional benefit

Brands

NanoImproved medicines: Nanoformed pharmaceutical products that improve drug performance through nanoparticle formulations.
Nanoapalutamide
Nanoenzalutamide
Nanotrastuzumab

Products and services

Nanoapalutamide
Nanoenzalutamide
Nanotrastuzumab
GMP Manufacturing Services

Quantifiable outcome

Nanotrastuzumab matches performance of Herceptin Hylecta
+1 more outcomes

Companies that use Nanoform

Customer profile

Segments1 record

Ideal customer profiles1 record

Nanoform technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Nanoform partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

Unnamed PartnerscoreStrategic or Co-development PartnerNanoform announced new partnerships focused on advancing localized therapy and high-concentration biologics delivery. The partnerships aim to leverage Nanoform's nanoforming technology for specialized pharmaceutical applications.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Nanoform competitors and assessment

Company assessment

Direct peers

Starpharma: Australia-listed company developing dendrimer-based nanoparticle drug delivery and DEP platform partnerships with major pharma. A direct comparable to Nanoform's platform-plus-partnerships business model in nanomedicine.
Camurus: Swedish specialty pharma company developing nanoparticle/fluid-crystal drug delivery formulations for improved bioavailability. Closely comparable to Nanoform as a Nordic-headquartered nanomedicine peer with both proprietary products and partnered formulation programs.
Cristal Therapeutics: European (Netherlands-based) clinical-stage company developing polymeric nanoparticle drug conjugates (CriPec platform) for oncology. Directly comparable to Nanoform as a nanoparticle-formulation platform targeting improved drug delivery.
NanoCarrier: Japanese clinical-stage biopharma developing micellar and nanoparticle drug delivery systems for oncology and other indications. Directly comparable to Nanoform in applying nanoparticle engineering to improve drug performance and delivery.

Others

Quotient Sciences:

Emerging players

CytoSorbents: US clinical-stage medtech/biotech using nanoporous polymer bead technology in therapeutic applications. Comparable as a small-cap public nanomedicine player with proprietary bead/particulate platform targeting pharma and critical care applications.
Ascendia Pharma: US-based specialty CDMO offering nanoemulsion, nanosuspension, and amorphous solid dispersion formulation development for poorly soluble drugs. Comparable to Nanoform's nanoforming platform and contract manufacturing services targeting bioavailability challenges.

Broad incumbents

Catalent: Large global pharma services CDMO offering formulation, bioavailability enhancement, and cGMP manufacturing including particle engineering. A broad incumbent comparable to Nanoform's contract manufacturing and formulation platform offering at materially larger scale.
Lonza (Bend Research): Global CDMO offering formulation development, particle engineering, and cGMP manufacturing for poorly soluble drugs via its Bend Research heritage. A broad incumbent comparable to Nanoform across the formulation-to-commercial-supply chain at greater scale.
PCI Pharma Services: Global CDMO providing drug development, manufacturing, and packaging services including specialized formulation and clinical-to-commercial supply. Comparable to Nanoform's cGMP manufacturing services for nanoformed APIs targeting pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Nanoform compliance and trust

Trust signal

Compliance2 records

Nanoform financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanoform leadership team

Management profile

Number of profiles

Profiles2 records

Nanoform funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanoform M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanoform

What does Nanoform do?

Is Nanoform a public or private company?

Nanoform is a private company. It is classified as public and is currently operating.

When was Nanoform founded?

Nanoform was founded in 2015. It employs 101 to 250 people.

Where is Nanoform based?

Nanoform is headquartered in Helsinki, Finland, in the Europe region.

How does Nanoform make money?

Three revenue lines are on record. NanoImproved Medicines Commercialization is the primary driver. The others are contract Manufacturing Services and R&D Collaboration and Licensing.

Who are Nanoform's main competitors?

Direct peers on record are Starpharma, Camurus, Cristal Therapeutics and NanoCarrier. Quotient Sciences is listed as an others. Emerging players are CytoSorbents and Ascendia Pharma. Broad incumbents are Catalent, Lonza (Bend Research) and PCI Pharma Services.

Does Nanoform have an API?

No public API is recorded for Nanoform.

What industry is Nanoform in?

Nanoform's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.